Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial Carcinomas

It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA‐damaging agents including cisplatin and doxorubicin. Overexpression of mdm2 oncoprotein, a negative regulator of p53, is assumed to be an alternative to p53 dys...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Jpn J Cancer Res
Päätekijät: Kakehi, Yoshiyuki, Özdemir, Enver, Habuchi, Tomonori, Yamabe, Hirohiko, Hashimura, Takayuki, Katsura, Yoshitaka, Yoshida, Osamu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 1998
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5921759/
https://ncbi.nlm.nih.gov/pubmed/9548450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.1998.tb00551.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia